NeuroVive Pharmaceutical AB Umsatz
Was ist das Umsatz von NeuroVive Pharmaceutical AB?
Umsatz von NeuroVive Pharmaceutical AB ist kr79.000k
Was ist die Definition von Umsatz?
Umsatz sind die Einnahmen, die ein Unternehmen aus seiner normalen Geschäftstätigkeit erzielt, normalerweise aus dem Verkauf von Waren und Dienstleistungen an Kunden.
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
Umsatz von Unternehmen in Health Care Sektor auf OTC im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit umsatz ähnlich NeuroVive Pharmaceutical AB
- Caravel Minerals hat Umsatz von AUD$76.264k
- Lodestar Minerals hat Umsatz von AUD$77.250k
- Checkpoint Therapeutics Inc hat Umsatz von $78.000k
- E2 Metals hat Umsatz von AUD$78.000k
- Sahara hat Umsatz von CAD$78.033k
- Gold Reserve hat Umsatz von $78.294k
- NeuroVive Pharmaceutical AB hat Umsatz von kr79.000k
- Paradigm Biopharmaceuticals hat Umsatz von AUD$79.224k
- Inhibikase Therapeutics hat Umsatz von $79.570k
- PuriflOH hat Umsatz von AUD$79.729k
- Basin hat Umsatz von AUD$79.935k
- Greencoat Renewables PLC hat Umsatz von €80.000k
- Venture Minerals hat Umsatz von AUD$80.000k